Gerresheimer's June Reckoning: Audit Delay, Divestiture, and the Fight for Creditor Confidence
13.06.2026 - 15:23:39 | boerse-global.de
Gerresheimer's shares ended last week at €25.14, a price that tells a story far removed from the company’s operational prospects. The pharma packaging specialist supplies sterile containers and connected injection systems for a booming market in complex biologics. Yet over twelve months the stock has shed nearly 47% of its value, dropping from a 52-week high of €50.25. Investors are not treating Gerresheimer as a growth story; they are treating it as a restructuring case on a tight leash.
The immediate trigger for the crisis lies in accounting. Gerresheimer prematurely recognised revenue from so-called bill-and-hold transactions, a violation of IFRS rules. An external law firm confirmed the systematic errors, which inflated revenue by €35 million and the adjusted operating result by €24 million. The audit watchdog is now investigating the company’s long-time auditor KPMG, adding another layer of uncertainty. The delayed financial statements cost Gerresheimer its place in a German small-cap index, slashing visibility and liquidity.
To relieve balance-sheet strain, management is pushing ahead with the sale of its US subsidiary Centor. The division, which generated high margins and was valued at €292 million in the books at the end of 2024, has attracted double-digit interested parties. Morgan Stanley is advising on the process. The dilemma is clear: selling Centor would cut debt but also compress the profitability of the remaining group.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Meanwhile, Gerresheimer is trying to reposition for the future through a new partnership with Newel Health focused on digital health data collection, particularly for GLP-1 drugs and Parkinson’s therapies. The aim is to move beyond pure packaging into value-added digital services.
Creditors have granted the company breathing room until the end of September 2026, suspending key loan covenants tied to leverage ratios. But the reprieve is conditional. Management is targeting revenue of up to €2.4 billion and an adjusted operating margin of just under 20% for 2026 — but only if the BaFin probe produces a clean outcome. Large investors such as Active Ownership and Goldman Sachs have recently positioned themselves, signalling they are watching closely.
Technically, the stock sits just below its 200-day moving average of €25.64, a crucial resistance level. It is marginally above the 50-day average of €23.97, preventing a slide into deeper bear territory, but no sustained uptrend has emerged. The market is not waiting for new orders; it is waiting for the audited financial statements, now expected by June 2026. A symbolic dividend of €0.04 per share does nothing to change the calculus.
The next few weeks will be decisive. If Gerresheimer delivers the audit, the steep discount on its equity could compress rapidly. If the deadline slips again, the creditor waivers may unravel by autumn. The company’s long-term demand drivers are intact, but the immediate test is boringly basic: absolute financial transparency is the only currency that can rebuild trust.
Ad
Gerresheimer Stock: New Analysis - 13 June
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
